Alpha Tau Treats First Immunocompromised Patient in New ADMIRE Skin Cancer Trial
DRTS has more than doubled off its 52-week low of $2.87.
Summary
Alpha Tau has dosed the first patient in its ADMIRE study, a new clinical trial evaluating its Alpha DaRT therapy in immunocompromised patients with recurrent cutaneous squamous cell carcinoma (cSCC). This expands the company's pipeline beyond the ReSTART pivotal trial, which recently completed enrollment. Immunocompromised patients, including organ transplant recipients, face up to 100-fold higher cSCC risk and have limited treatment options due to contraindications for checkpoint inhibitors. The ADMIRE study directly addresses this unmet need. The procedure was performed at Banner MD Anderson Cancer Center, a site already experienced with Alpha DaRT from the ReSTART trial. This milestone follows a series of positive clinical and regulatory updates over the past two months, including encouraging pancreatic cancer data and a U.S. commercialization deal with Tolmar.
At the time of this announcement, DRTS was trading at $12.87 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.1B. The 52-week trading range was $2.87 to $14.11. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.